Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies

Cancer Research

Volumn 59, Issue 8, 1999, Pages 1954-1960

  Paul, Pascale ^a   Cabestré, Francisco Adrián ^a   Le Gal, Fréderique Anne ^b   Khalil Daher, Iman ^a   Le Danff, Caroline ^a   Schmid, Michel ^d   Mercier, Sylvaine ^c   Avril, Marie Françoise ^c   Dausset, Jean ^e   Guillet, Jean Gérard ^b   Carosella, Edgardo D ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Centre Hayem   (France)

^e FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; RNA, MESSENGER; SKIN; TRANSCRIPTION, GENETIC; VARIATION (GENETICS);

EID: 0033561532     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ferrone, S., and Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, Immunol. Today, 16: 487-494, 1995.
2. Maeurer, M., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., and Lotze, M. T. Tumor escape from immune recognition. J. Clin. Invest., 98: 1633-1641, 1996.
3. Seliger, B., Maeurer, M. J., and Ferrone, S. TAP off-tumors on, Immunol. Today, 18: 292-298, 1997.
4. Hicklin, D., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., and Ferrone, S. β2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest., 15: 2720-2729, 1998.
5. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18: 175-182, 1997.
6. Pardoll, D. M. Cancer vaccines. Nat. Med., 4: 525-531, 1998.
7. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327, 1998.
8. Alexandroff, A. B., Robins, R. A., Murray, A., and James, K. Tumour immunology: false hopes, new horizons. Immunol. Today, 19: 247-252, 1998.
9. Rivoltini, L., Loftus, D., Squarcina, P., Castelli, C., Rini, F., Arienti, F., Belli, F., Marincola, F., Geisler, C., Borsatti, A., Appella, E., and Parmiani, G. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Crit. Rev. Immunol., 18: 55-63, 1998.
10. Nestle, F. O., Aligajic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
11. Tüling, T., Wilson, C. C., Martin, D. M., Kasamon, Y. L., Rowles, J., Ma, D. I., Slingluff, C. L., Wagner, S. N., van der Bruggen, P., Baar, J., Lotze, M. T., and Storkus, W. J. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol., 160: 1139-1147, 1998.
12. Ruiz Cabello, F., and Garrido, F. HLA and cancer: from research to clinical impact. Immunol. Today, 19: 539-542, 1998.
13. Porgador, A., Mandelboim, O., Restifo, N., and Strominger, J. L. Natural killer cell lines kill autologous β2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA, 94: 13140-13145, 1997.
14. Klein, E., and Mantovani, A. Action of natural killer cells and macrophages in cancer. Curr. Opin. Immunol., 5: 714-718, 1993.
15. Bakker, A. B. H., Phillips, J. H., Figdor, C. G., and Lanier, L. L. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ T cells, and antigen-specific CTL. J. Immunol., 160: 5239-5245, 1998.
16. Pende, D., Accame, L., Pareti, L., Mazzochi, A., Moretta, A., Parmiani, G., and Moretta, L. The susceptibility to natural killer cell-mediated lysis of HLA class I positive melanomas reflects the insufficient amounts of different HLA class I alleles. Eur. J. Immunol., 28: 2384-2394, 1998.
17. Ikeda, H., Lethe, B., Lehmann, F., van Baren, N., Baurain, J. F., de Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., and Coulie, P. G. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6: 199-208, 1997.
18. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Vjllar, J. J., Lopez-Botet, M., Duggan-Keen, M., and Stern, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18: 89-95, 1997.
19. Paul, P., Rouas-Freiss, N., Khalil-Daher, I., Moreau, P., Riteau, B., Le Gal, F. A., Avril, M. F., Dausset, J., Guillet, J. G., and Carosella, E. D. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA, 95: 4510-4515, 1998.
20. Carosella, E. D., Dausset, J., and Kirszenbaum, M. HLA-G revisited. Immunol. Today, 17: 407-409, 1996.
21. Natali, P., Bigotti, A., Nicotra, M., Viora, M., Manfredi, D., and Ferrone, S. Distribution of human class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res., 44: 4679-4687, 1984.
22. Crisa, L., McMaster, M. T., Ishii, J. K., Fisher, S. J., and Salomon, D. R. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J. Exp. Med., 186: 289-298, 1997.
23. Blaschitz, A., Lenfant, F., Mallet, V., Hartmann, M., Bensussan, A., Geraghty, D. E., Le Bouteiller, P., and Dohr, G. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur. J. Immunol., 27: 3380-3388, 1997.
24. Yang, Y., Chu, W., Geraghty, D. E., and Hunt, J. S. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-γ. J. Immunol., 156: 4224-4231, 1996.
25. Cantoni, C., Verdiani, S., Falco, M., Pessino, A., Cilli, M., Conte, R., Pende, D., Ponte, M., Mikaelsson, M. S., Moretta, L., and Biassoni, R. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the Ig superfamily. Eur. J. Immunol., 28: 1980-1990, 1998.
26. Colonna, M., Samaridis, J., Cella, M., Angman, L., Allen, R. L., O'Callaghan, C., Dunbar, R., Ogg, G. S., Cerundolo, V., and Rolink, A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol., 160: 3096-3100, 1998.
27. Colonna, M., Navarro, F., Bellon, T., Llano, M., Garcia, P., Samaridis, J., Angman, L., Cella, M., and Lopez-Botet, M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med., 186: 1809-1818, 1997.
28. Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., Lanier, L. L., and McMichael, A. J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature (Lond.), 391: 795-799, 1998.
29. Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., Lopez-Botet, M., and Geraghty, D. E. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA, 95; 5199-5204, 1998.
30. O'Callaghan, C. A., and Bell, J. I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol. Rev., 163: 129-138, 1998.
31. Skelton, H. d., Smith, K., Barrett, T., Lupton, G. P., and Graham, J. H. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation. Am. J. Dermatopathol., 13: 543-550, 1991.
32. Lee, N., Malacko, A. R., Ishitani, A., Chen, M. C., Bajorath, J., Marquardt, H., and Geraghty, D. E. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity, 3: 591-600, 1995.
33. Amiot, L., Onno, M., Drénou, B., Lemarchand, B., Lamy, T., Semana, G., and Fauchet, R. Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid cell-derived leukemia. Eur. J. Immunogenet., 23: 311-320, 1996.
34. Kirszenbaum, M., Moreau, P., Gluckman, E., Dausset, J., and Carosella, E. D. An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc. Natl. Acad. Sci. USA, 91: 4209-4213, 1994.
35. Amiot, L., Onno, M., Drénou, B., Monvoisin, C., and Fauchet, R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum. Immunol., 59: 524-528, 1998.
36. Carosella, E. D., Rouas-Freiss, N., Paul, P., and Dausset, J. HLA-G: a tolerance molecule from the major histocompatibilily complex. Immunol. Today, 20: 60-62, 1999.
37. Fukushima, Y., Oshika, Y., Nakamura, M., Tokunaga, T., Hatanaka, H., Abe, Y., Yamazaki, H., Kijima, H., Ueyama, Y., and Tamaoki, N. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int. J. Mol. Med., 2: 349-351, 1998.
38. Amiot, L., Onno, M., Renard, I., Drénou, B., Guillaudeux, T., Lebouteiller, P., and Fauchet, R. HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens, 47: 408-413, 1996.
39. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor escape. Science, 274: 1363, 1996.
40. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., and Blay, J. I. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today, 18: 493-497, 1997.
41. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrelo, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA, 95: 1178-1183, 1998.
42. De Smet, C., De Backer, O., Faraoni, I., Lurquin, C., Brasseur, F., and Boon, T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation, Proc. Natl. Acad. Sci. USA, 93: 7149-7153, 1996.
43. Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L., and Hsu, M-I. A novel Ig superfamily receptor for cellular and viral MHC class I molecules. Immunity, 7: 273-283, 1997.
44. Yokoyama, W. M. HLA class I specificity for natural killer cell receptor CD94/ NKG2A: two for one in more ways than one. Proc. Natl. Acad. Sci. USA, 95: 4791-4794, 1998.
45. Chu, W., Fant, M. E., Geraghty, D. E., and Hunt, J. S. Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-γ-activated macrophages but not placental fibroblasts. Hum. Immunol., 59: 435-442, 1998.
46. Houlihan, J. M., Biro, P. A., Harper, H. M., Jenkinson, H. J., and Holmes, C. H. The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. J. Immunol., 154: 5665-5674, 1995.
47. Brasoveanu, L. I., Fonsatti, E., Vasintin, A., Pavlovic, M., Cattarossi, I., Colizzi, F., Gasparollo, A., Coral, S., Horejsi, V., Altomonte, M., and Maio, M. Melanoma cells constitutively release an anchor-positive soluble form of protein (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J. Clin. Invest., 100: 1248-1255, 1997.
48. Bernhard, H., Meyer zum Buschenfelde, K., and Dippold, W. G. Ganglioside GD3 shedding by human malignant melanoma cells. Int. J. Cancer, 44: 155-160, 1989.
49. Westhoff, U., Fox, C., and Otto, F. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res., 18: 3789-3792, 1998.
50. Becker, J., and Brocker, E. Lymphocyte-melanoma interaction: role of surface molecules. Rec. Results Cancer Res., 139: 105-114, 1995.
51. Carbone, E., Terrazzano, G., Colonna, M., Tuosto, L., Piccolella, E., Franksson, L., Pérez-Villar, J. J., Fontana, S., Karre, K., and Zappacosta, S. Natural killer clones recognize specific soluble HLA class I molecules, Eur. J. Immunol., 26: 683-689, 1996.
52. Mc Donald, J., and Adamashvili, I. Soluble HLA: a review of the literature. Hum. Immunol., 59: 387-403, 1998.
53. Zavazava, N., and Krönke, M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat. Med., 2: 1005-1010, 1996.
54. Puppo, F., Indiveri, F., Scudeletti, M., and Ferrone, S. Soluble HLA-G antigens: new roles and uses. Immunol. Today, 18: 154-155, 1997.